-
1
-
2
miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting
Published 2025-02-01Subjects: Get full text
Article -
3
Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia
Published 2025-12-01Subjects: Get full text
Article -
4
BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies
Published 2025-01-01Subjects: Get full text
Article